These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1174440)

  • 1. Protection of mice against cancer by immunization with membranes but not purified virions from virus infected cancer cells.
    Griffith IP; Crook NE; White DO
    Br J Cancer; 1975 Jun; 31(6):603-13. PubMed ID: 1174440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge.
    Grosfeld H; Velan B; Leitner M; Cohen S; Lustig S; Lachmi BE; Shafferman A
    J Virol; 1989 Aug; 63(8):3416-22. PubMed ID: 2473217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.
    Zhou X; Berglund P; Zhao H; Liljeström P; Jondal M
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):3009-13. PubMed ID: 7708765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis.
    Boere WA; Benaissa-Trouw BJ; Harmsen M; Kraaijeveld CA; Snippe H
    J Gen Virol; 1983 Jun; 64 (Pt 6)():1405-8. PubMed ID: 6854274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response to spike protein vaccines prepared from Semliki Forest virus.
    Balcarova J; Helenius A; Simons K
    J Gen Virol; 1981 Mar; 53(Pt 1):85-92. PubMed ID: 6268742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of membrane fractions with enhanced tumor-transplantation-antigen activity from tumor cells infected with influenza virus.
    Boone CW; Orme TW; Blackman K; Gillette R
    J Natl Cancer Inst; 1973 Oct; 51(4):1141-4. PubMed ID: 4355600
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor-specific transplantation antigen: use of the Ad2+ND1 hybrid virus to identify the protein responsible for simian virus 40 tumor rejection and its genetic origin.
    Jay G; Jay FT; Chang C; Friedman RM; Levine AS
    Proc Natl Acad Sci U S A; 1978 Jul; 75(7):3055-9. PubMed ID: 80009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine.
    Snijders A; Benaissa-Trouw BJ; Oosterlaken TA; Puijk WC; Posthumus WP; Meloen RH; Boere WA; Oosting JD; Kraaijeveld CA; Snippe H
    J Gen Virol; 1991 Mar; 72 ( Pt 3)():557-65. PubMed ID: 1706409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus.
    Boere WA; Benaissa-Trouw BJ; Harmsen T; Erich T; Kraaijeveld CA; Snippe H
    Immunology; 1986 Aug; 58(4):553-9. PubMed ID: 3015781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
    Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
    Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.
    Snijders A; Benaissa-Trouw BJ; Visser-Vernooy HJ; Fernandez I; Snippe H; Kraaijeveld CA
    Immunology; 1992 Nov; 77(3):322-9. PubMed ID: 1282493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protection correlates with delayed antibody formation to challenge virus after immunization with Sindbis virus.
    Smith-Owirodu A; Wust CJ; Gates D; Brown A
    J Gen Virol; 1980 Dec; 51(Pt 2):351-7. PubMed ID: 7229617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis.
    Eisenlohr LC; Hackett CJ
    J Exp Med; 1989 Mar; 169(3):921-31. PubMed ID: 2784481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection of cultured murine brain cells by Semliki Forest virus: effects of interferon-alpha beta on viral replication, viral antigen display, major histocompatibility complex antigen display and lysis by cytotoxic T lymphocytes.
    Morris A; Tomkins PT; Maudsley DJ; Blackman M
    J Gen Virol; 1987 Jan; 68 ( Pt 1)():99-106. PubMed ID: 3492589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.
    Acres RB; Hareuveni M; Balloul JM; Kieny MP
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):136-43. PubMed ID: 8280702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice.
    Cabrera A; Sáez D; Céspedes S; Andrews E; Oñate A
    Immunobiology; 2009; 214(6):467-74. PubMed ID: 19150742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.
    Boere WA; Benaissa-Trouw BJ; Harmsen T; Erich T; Kraaijeveld CA; Snippe H
    J Virol; 1985 May; 54(2):546-51. PubMed ID: 2985817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens.
    Smith ML; Corbo T; Bernales J; Lindbo JA; Pogue GP; Palmer KE; McCormick AA
    Virology; 2007 Feb; 358(2):321-33. PubMed ID: 17014881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.